A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
AbbVie
AbbVie
Zhejiang University
Fudan University
Third Affiliated Hospital, Sun Yat-Sen University
Eisai Inc.
OHSU Knight Cancer Institute
Tongji Hospital
Eisai Inc.
Fudan University
Beijing Tsinghua Chang Gung Hospital
H. Lee Moffitt Cancer Center and Research Institute
Tianjin Medical University Cancer Institute and Hospital
Ruijin Hospital